Carregant...
BET bromodomain inhibitors—A novel epigenetic approach in castration-resistant prostate cancer
The androgen receptor (AR) is central to the initiation and progression of prostate cancer, even after castration. There has been some success in therapies targeting AR signaling which have been shown to extend survival in men with castration-resistant prostate cancer (CRPC). However, durable respon...
Guardat en:
| Publicat a: | Cancer Biol Ther |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622075/ https://ncbi.nlm.nih.gov/pubmed/25535892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.962297 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|